Innovent Biologics Inc. (IVBXF)

PNK: IVBXF · Real-Time Price · USD

6.88

0.91 (15.15%)

At close: May 01, 2025, 12:59 PM

Innovent Biologics Income Statement

Financials in CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Revenue	6.21B	4.56B	4.27B	3.84B	1.05B	9.48M	18.54M	32.13M
Cost of Revenue	1.14B	930.99M	573.04M	387.76M	124.88M	-1.31M	-71.47M	n/a
Gross Profit	5.07B	3.63B	3.7B	3.46B	922.65M	10.79M	90.01M	32.13M
Operating Income	-909.21M	-2.07B	-3.11B	-820.14M	-1.66B	-1.79B	-750.14M	-461.54M
Interest Income	452.84M	189.54M	151.75M	116.1M	102.7M	20.68M	7.98M	4.54M
Pretax Income	-1.14B	-2.17B	-3.05B	-858.71M	-1.72B	-5.87B	-716.05M	-544.46M
Net Income	-1.03B	-2.18B	-3.14B	-998.42M	-1.78B	-5.77B	-562.32M	-504.2M
Selling & General & Admin	3.85B	3.43B	3.61B	1.78B	1.45B	413.51M	87.77M	57.38M
Research & Development	2.23B	2.87B	2.48B	1.85B	1.29B	1.22B	611.92M	384.65M
Other Expenses	-99.51M	-90.2M	-45.13M	-130.69M	-41.38M	-4.34B	-51.01M	-123.2M
Operating Expenses	5.98B	6.21B	6.05B	3.5B	2.7B	1.56B	643.27M	413.27M
Interest Expense	98.62M	101.7M	62.46M	68.35M	59.49M	68.97M	57.23M	53.8M
Selling & Marketing Expenses	3.1B	2.59B	2.73B	1.34B	1.19B	136.01M	9.94M	5.03M
Cost & Expenses	7.12B	7.14B	6.62B	3.89B	2.83B	1.56B	643.27M	413.27M
Income Tax Expense	-116.5M	8.8M	87.04M	139.71M	56.86M	27.48M	-244.37M	-150.97M
Shares Outstanding (Basic)	1.56B	1.49B	1.45B	1.35B	1.18B	334.68M	1.12B	1.12B
Shares Outstanding (Diluted)	1.56B	1.49B	1.46B	1.36B	1.18B	334.68M	1.12B	1.12B
EPS (Basic)	-0.66	-1.46	-2.16	-0.74	-1.51	-17.24	-0.5	-0.45
EPS (Diluted)	-0.66	-1.46	-2.16	-0.74	-1.51	-17.24	-0.5	-0.45
EBITDA	-660.68M	-1.75B	-2.37B	-704.74M	-1.57B	-5.74B	-597.72M	-359.92M
EBIT	-1.05B	-2.07B	-2.58B	-790.36M	-1.66B	-5.8B	-658.83M	-413.27M
Depreciation & Amortization	385.1M	319.42M	204.75M	85.63M	86.37M	64.06M	61.1M	53.35M